Integrated DNA Technologies (IDT), a Danaher company and a global leader in genomics, has announced the publication of a peer-reviewed study establishing a new analytical performance benchmark for CRISPR off-target nomination, providing evidence that can help gene editing developers prioritise biologically relevant sites for downstream confirmation and risk assessment. Published in the journal Nature Communications, the work addresses a critical…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.